UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Annals of oncology, 2021-07, Vol.32 (7), p.881-895

2021

Volltextzugriff (PDF)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1311-1320

2019

Volltextzugriff (PDF)

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

European journal of cancer (1990), 2015-11, Vol.51 (16), p.2321-2329

2015

Volltextzugriff (PDF)

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Annals of oncology, 2012-11, Vol.23 (11), p.2834-2842

2012

Volltextzugriff (PDF)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281-289

2019

Volltextzugriff (PDF)

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of oncology, 2016-07, Vol.27 (7), p.1291-1298

2016

Volltextzugriff (PDF)

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Annals of oncology, 2017-12, Vol.28 (12), p.2932-2942

2017

Volltextzugriff (PDF)

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Annals of oncology, 2016-09, Vol.27 (9), p.1712-1718

2016

Volltextzugriff (PDF)

Salivary diagnostics

Orthodontics & craniofacial research, 2009-08, Vol.12 (3), p.206-211

2009

Volltextzugriff (PDF)

IBS04.01 Biological Mechanisms

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S92-S92

Garon, E.

2019

Volltextzugriff (PDF)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

Cancer treatment and research communications, 2021, Vol.27, p.100378, Article 100378

2021

Volltextzugriff (PDF)

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii741-viii742

2018

Volltextzugriff (PDF)

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

Annals of oncology, 2018-10, Vol.29, p.viii529-viii530

2018

Volltextzugriff (PDF)

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

Annals of oncology, 2018-10, Vol.29, p.viii749-viii749

2018

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Annals of oncology, 2019-04, Vol.30, p.ii79-ii80

2019

Volltextzugriff (PDF)

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

ESMO open, 2023-08, Vol.8 (4), p.101580-101580, Article 101580

2023

Volltextzugriff (PDF)

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

Annals of oncology, 2018-11, Vol.29, p.ix164-ix164

2018

Volltextzugriff (PDF)

Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results

Annals of oncology, 2017-10, Vol.28, p.vi56-vi56

2017

Volltextzugriff (PDF)

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of oncology, 2018-10, Vol.29, p.viii407-viii407

2018

Volltextzugriff (PDF)

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S216-S217

2019

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092

2018

Volltextzugriff (PDF)

Incidental Mediastinal Dose Does Not Explain Low Mediastinal Nodal Recurrence Rates in Early-Stage NSCLC Patients Treated With SBRT

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S35-S35

2013

Volltextzugriff (PDF)

MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S16-S17

2021

Volltextzugriff (PDF)

Pilot study: Assessing if a previously validated questionnaire, Index of Clinical Trial Understanding (ICTU), measures understanding in elderly patients with metastatic Non-Small Cell Lung Cancer (NSCLC)

Journal of geriatric oncology, 2013-10, Vol.4, p.S22-S23

2013

Volltextzugriff (PDF)

1 – 25 von 426

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(370)
Mit Volltextzugriff
(372)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(139)
Life Sciences & Biomedicine
(119)
Humans
(101)
Female
(54)
Male
(53)
Oncology
(49)
Middle Aged
(34)
Adult
(31)
Aged
(30)
Biological And Medical Sciences
(30)
Lung Neoplasms - Drug Therapy
(30)
Social Sciences
(29)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(28)
Psychology
(28)
Animals
(23)
Lung Cancer
(19)
Lung Neoplasms - Pathology
(18)
Psychology, Developmental
(18)
Rheumatology
(17)
Aged, 80 And Over
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Salivary diagnostics

IBS04.01 Biological Mechanisms

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Incidental Mediastinal Dose Does Not Explain Low Mediastinal Nodal Recurrence Rates in Early-Stage NSCLC Patients Treated With SBRT

MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

Pilot study: Assessing if a previously validated questionnaire, Index of Clinical Trial Understanding (ICTU), measures understanding in elderly patients with metastatic Non-Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern